SCHEMBL3009367

SCHEMBL3009367

O=S(=O)(c1cccc(C(F)(F)F)c1)C1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.56
AR P10275 1/20 0.51
MAPT P10636 5/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CTSS P25774 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
MAPK1 P28482 2/20 0.47
VCP P55072 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KCNQ1 P51787 1/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FFAR2 O15552 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008360 0.94 AR (0.52) KDM1AARMAPTRAB9ANPC1
SCHEMBL3017305 0.92 AR (0.56) KDM1AARRAB9ANPC1CYP1A2
SCHEMBL3011795 0.91 AR (0.50) KDM1AARMAPTRAB9ANPC1
SCHEMBL3011000 0.91 AR (0.52) KDM1AARMAPTRAB9ANPC1
SCHEMBL3019382 0.91 SMN1; SMN2 (0.51) KDM1AARMAPTRAB9ANPC1
SCHEMBL3013920 0.90 AR (0.52) KDM1AARMAPTRAB9ANPC1
SCHEMBL3005260 0.89 AR (0.50) KDM1AARMAPTRAB9ANPC1
SCHEMBL3003773 0.89 AR (0.48) KDM1AARMAPTRAB9ANPC1
SCHEMBL3015722 0.88 SMN1; SMN2 (0.55) KDM1AMAPTRAB9ANPC1CYP1A2
SCHEMBL3018292 0.88 AR (0.48) KDM1AARMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM1A 3548/4885AR 3801/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.